(RTTNews) - Quest Diagnostics (DGX) said, for full year 2025, the company now expects adjusted EPS in a range of $9.63 $9.83, revised from prior guidance range of $9.55 $9.80. Net revenues are now projected in a range of $10.80 billion $10.92 billion, updated from prior guidance range of $10.70 billion $10.85 billion.
For the second quarter, the company's bottom line came in at $282 million, or $2.47 per share. This compares with $229 million, or $2.03 per share, last year. Excluding items, Quest reported adjusted earnings of $298 million or $2.62 per share for the period. Revenue for the period rose 15.2% to $2.76 billion from $2.40 billion last year.
"Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15.2% which includes 5.2% from organic revenues, as well as adjusted EPS growth of 11.5%," said Jim Davis, Chairman, CEO and President.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
